Dare Bioscience, Inc. SEC filings DARE
Dare Bioscience, Inc. has 777 filings in SEC EDGAR's recent list, going back to May 29, 2007. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 2, 2026 (listing notice). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Oct 27, 2026 | — |
| DEF 14A | Proxy statement | Oct 6, 2026 | Oct 6, 2026 |
| PRE 14A | Preliminary proxy statement | Sep 23, 2026 | Sep 23, 2026 |
| DEFA14A | Additional proxy material | Jun 1, 2026 | — |
| DEFA14A | Additional proxy material | Jun 1, 2026 | — |
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Jun 11, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2026 | Jun 11, 2026 |
| DEFA14A | Additional proxy material | Jun 12, 2025 | — |
| DEFA14A | Additional proxy material | Apr 24, 2025 | — |
| DEF 14A | Proxy statement | Apr 24, 2025 | Jun 12, 2025 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 5, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 16, 2024 | Jun 5, 2024 |
| DEFA14A | Additional proxy material | Apr 27, 2023 | — |
| DEF 14A | Proxy statement | Apr 27, 2023 | Jun 21, 2023 |
| DEFA14A | Additional proxy material | Jun 28, 2022 | — |
| DEFA14A | Additional proxy material | Jun 24, 2022 | — |
| DEFA14A | Additional proxy material | Jun 22, 2022 | — |
| DEFA14A | Additional proxy material | Jun 21, 2022 | — |
| DEFA14A | Additional proxy material | Apr 29, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 23, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 15, 2022 | Jun 23, 2022 |
| DEFA14A | Additional proxy material | May 14, 2021 | — |
| DEF 14A | Proxy statement | May 14, 2021 | Jun 24, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 23, 2021 | Jun 24, 2021 |
| DEFA14A | Additional proxy material | Apr 22, 2020 | — |
| DEF 14A | Proxy statement | Apr 22, 2020 | Jun 25, 2020 |
| DEFA14A | Additional proxy material | Jun 3, 2019 | — |
| DEFA14A | Additional proxy material | Apr 30, 2019 | — |
| DEF 14A | Proxy statement | Apr 30, 2019 | Jun 13, 2019 |
| DEFA14A | Additional proxy material | May 31, 2018 | — |
| DEF 14A | Proxy statement | May 31, 2018 | Jul 10, 2018 |
| DEFA14A | Additional proxy material | Jul 5, 2017 | — |
| DEFA14A | Additional proxy material | Jun 27, 2017 | — |
| DEFA14A | Additional proxy material | Jun 19, 2017 | — |
| DEFM14A | Filing | Jun 19, 2017 | — |
| DEFA14A | Additional proxy material | May 8, 2017 | — |
| PREM14A | Filing | Apr 17, 2017 | Apr 17, 2017 |
| DEFA14A | Additional proxy material | Mar 24, 2017 | — |
| DEFA14A | Additional proxy material | Mar 21, 2017 | — |
| DEFA14A | Additional proxy material | Mar 20, 2017 | — |
| DEFA14A | Additional proxy material | Apr 28, 2016 | — |
| DEF 14A | Proxy statement | Apr 28, 2016 | Jun 22, 2016 |
| DEFA14A | Additional proxy material | May 5, 2015 | — |
| DEF 14A | Proxy statement | May 5, 2015 | Jun 26, 2015 |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DARE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1401914
- Former names
- Cerulean Pharma Inc. (until Jul 5, 2017); Tempo Pharmaceuticals Inc (until Jan 22, 2008)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.